Boti

Bonti, Inc. was a Newport Beach, California-based clinical-stage biotechnology company founded in 2015 that developed EB-001, a fast-acting, short-duration botulinum neurotoxin of serotype E for cosmetic and therapeutic use, positioned as an alternative to longer-lasting neuromodulators like Botox. The company raised roughly $36 million in funding before Allergan plc acquired it in October 2018 for $195 million upfront, adding new neurotoxin programs to Allergan's medical aesthetics pipeline.